' EQUITYPreferred stock, 7,000,000 shares
authorized, zero shares issued and
outstanding--Common stock, $0.01 par value; 150
million shares authorized,
48,366,304 and 46,897,529 shares
outstanding in 2011 and 2010 respectively483,663468,975Additional paid-in capital97,248,33493,339,506Accumulated deficit(89,055,933)(85,954,131)Total stockholders' equity8,676,0647,854,350Total liabilities and stockholders' equity$
9,710,037
$
10,591,360Neuralstem, Inc.Statements of OperationsThree MonthsEnded March 31,2011
2010Revenues
$
-
$
-Operating expenses:Research and development costs
1,738,728
1,899,963General and administrative expenses
1,772,482
1,687,835Depreciation and amortization
25,293
29,063Total operating expenses
3,536,503
3,616,861Operating loss
(3,536,503)
(3,616,861)Nonoperating income (expense):Litigation settlement
250,000
-Interest income
22,892
5,811Interest expense
-
(659)Warrant issuance and modification expense
-
(1,906,800)Gain (loss) from change in fair value adjustment of warrant obligations
161,809
(1,248,452)Total nonoperating income (expense)
434,701
(3,150,100)Net loss attributable to common shareholders
$ (3,101,802)
$ (6,766,961)Net loss per share - basic and diluted
$
(0.07)
$
(0.18)Weighted average common shares outstanding - basic and diluted
47,692,878
38,539,226
'/>"/>
SOURCE Neuralstem, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board2.
Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.3.
Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress4.
Neuralstem Completes $5.25 Million Financing5.
Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update6.
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial7.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.8.
Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference9.
Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent10.
Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit11.
Neuralstem Reports Second Quarter Financial Results and Highlights